docetaxel anhydrous has been researched along with mln 8237 in 6 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (mln 8237) | Trials (mln 8237) | Recent Studies (post-2010) (mln 8237) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 246 | 43 | 236 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | mln 8237 (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.0088 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.32 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | 0.49 | |
| Ephrin type-A receptor 2 | Homo sapiens (human) | 0.048 | |
| Aurora kinase A | Mus musculus (house mouse) | 0.001 | |
| Aurora kinase B | Homo sapiens (human) | 0.5416 | |
| Inner centromere protein | Homo sapiens (human) | 0.0011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cooke, LS; Liu, X; Mahadevan, D; Manziolli, A; Miller, TP; Persky, DO; Qi, W; Rimsza, L; Roe, DJ | 1 |
| Cooke, LS; Fisher, RI; Mahadevan, D; Manziello, A; Miller, TP; Morales, C; Persky, DO; Qi, W; Stejskal, A | 1 |
| Belkhiri, A; Ecsedy, J; El-Rifai, W; Katsha, A; Sehdev, V; Zaika, A | 1 |
| Chakravarty, A; Dorner, A; Ecsedy, JA; Huck, JJ; Hyer, ML; Kannan, K; Kleinfield, R; Manfredi, MG; Mettetal, J; Shinde, V; Shyu, WC; Venkatakrishnan, K; Zhang, M; Zhou, X | 1 |
| Graff, JN; Hahn, NM; Higano, CS; Leonard, EJ; Sarantopoulos, J; Taylor, MH; Venkatakrishnan, K; Zhang, B; Zhou, X | 1 |
1 trial(s) available for docetaxel anhydrous and mln 8237
| Article | Year |
|---|---|
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Biomarkers; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Grading; Neoplasm Staging; Neoplasms; Pyrimidines; Taxoids; Treatment Outcome | 2016 |
5 other study(ies) available for docetaxel anhydrous and mln 8237
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Taxoids | 2011 |
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin D1; Docetaxel; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Spindle Apparatus; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2012 |
The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle Checkpoints; Cell Survival; Docetaxel; Female; Gastrointestinal Neoplasms; Humans; Mice; Mice, Nude; Polyploidy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Topics: Animals; Antineoplastic Agents; Area Under Curve; Aurora Kinase A; Azepines; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Female; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Pyrimidines; Taxoids; Translational Research, Biomedical | 2014 |